toxic
multipl
myeloma
p
omalidomid
gener
immunomodulatori
agent
imid
use
manag
multipl
myeloma
refractori
lenalidomid
bortezomib
pomalidomideinduc
pulmonari
toxic
extrem
rare
patient
usual
present
nonspecif
symptom
mimick
pneumonia
respiratori
failur
previou
report
acut
lung
toxic
relat
pomalidomid
drug
increasingli
use
multipl
myeloma
import
recogn
yet
unknown
sever
advers
reaction
time
manner
avoid
signific
morbid
patient
articl
author
report
addit
case
pomalidomideinduc
pulmonari
toxic
base
tempor
relationship
drug
administr
onset
symptom
well
characterist
imag
find
side
effect
new
undiscov
addit
studi
need
recogn
entiti
earlier
diseas
cours
man
histori
igg
kappa
multipl
myeloma
mm
present
progress
dyspnea
product
cough
day
patient
initi
pomalidomid
month
present
receiv
multipl
line
therapi
sinc
time
diagnosi
initi
receiv
bortezomib
liposom
doxorubicin
dexamethason
good
respons
develop
diseas
relaps
month
later
start
lenalidomid
dexamethason
treatment
complic
multipl
infect
therapi
place
hold
resum
month
later
rise
serum
protein
three
month
later
rise
protein
cyclophosphamid
ad
regimen
achiev
partial
respons
subsequ
underw
autolog
stem
cell
transplant
highdos
melphalan
condit
remain
therapi
year
initi
bortezomib
bendamustin
dexamethason
diseas
relaps
howev
switch
lenalidomid
bortezomib
dexamethason
brief
durat
minim
respons
prior
regimen
respond
partial
latter
regimen
subsequ
dexamethason
stop
lenalidomid
bortezomib
mainten
continu
month
current
present
develop
relaps
lenalidomid
bortezomib
discontinu
initi
pomalidomid
mgd
day
dexamethason
mg
weekli
approxim
month
start
treatment
pomalidomid
patient
develop
fever
progress
dyspnea
product
cough
gener
weak
day
durat
present
hospit
physic
examin
temperatur
heart
rate
respir
satur
room
temperatur
patient
sever
respiratori
distress
lung
examin
show
poor
chest
expans
diminish
breath
sound
bilater
lung
base
chest
film
show
right
upper
lobe
left
parahilar
infiltr
ventil
perfus
vq
scan
low
probabl
pulmonari
embol
laboratori
studi
within
normal
limit
includ
white
blood
cell
count
kcumm
refer
rang
kcumm
eosinophil
count
sputum
blood
cultur
unrev
patient
empir
treat
broad
spectrum
antibiot
communityacquir
pneumonia
initi
requir
noninvas
posit
pressur
ventil
maintain
appropri
oxygen
pomalidomid
held
time
minim
immunosuppress
sever
infecti
process
patient
gradual
improv
symptom
discharg
day
hospit
within
week
patient
reiniti
pomalidomid
week
restart
medic
develop
recurr
symptom
physic
examin
patient
febril
tachycard
tachypn
hypox
requir
supplement
oxygen
lung
examin
reveal
coars
breath
sound
bilater
laboratori
abnorm
includ
white
blood
cell
count
kcumm
absolut
neutrophil
count
kcumm
refer
rang
kcumm
absolut
eosinophil
count
hemoglobin
gdl
refer
rang
gdl
platelet
count
kcumm
refer
rang
kcumm
creatinin
highresolut
computer
tomographi
chest
show
interstiti
chang
bilater
upper
lobe
ground
glass
opac
figur
given
concern
infecti
etiolog
multipl
studi
perform
includ
urin
pneumococc
legionella
antigen
influenza
b
pcr
respiratori
syncyti
viru
rsv
pcr
serum
aspergillu
antigen
serum
cytomegaloviru
cmv
pcr
parvoviru
pcr
serum
beta
glucan
neg
transthorac
echocardiographi
show
normal
cardiac
function
vq
scan
show
low
probabl
pulmonari
embol
patient
empir
start
broad
spectrum
antibiot
pomalidomid
discontinu
minim
immunosuppress
presum
activ
infecti
process
fiberopt
bronchoscopi
perform
bronchoalveolar
lavag
bal
neg
cmv
dfa
pneumocysti
cariini
stain
herp
simplex
viru
ii
adenoviru
coronaviru
rsv
influenza
human
metapneumoviru
rhinoviru
parainfluenza
viru
chlamydia
mycoplasma
acid
fast
bacilli
aspergillu
fumig
legionella
bal
cell
count
differenti
perform
lung
tissu
biopsi
show
chronic
interstiti
pneumonia
focal
featur
organ
pneumonia
figur
patient
improv
day
discharg
home
oral
antibiot
pomalidomid
held
acut
ill
resum
outpati
set
one
month
later
patient
admit
time
similar
symptom
repeat
ct
scan
chest
demonstr
bilater
ground
glass
opac
patient
recurr
resolut
symptom
tempor
relationship
therapi
pomalidomid
along
ground
glass
opac
ct
led
strong
suspicion
pomalidomideinduc
pulmonari
toxic
patient
start
prednison
mgkg
result
signific
clinic
improv
pomalidomid
discontinu
perman
pomalidomid
gener
immunomodulatori
agent
mechan
action
includ
angiogenesi
inhibit
immunomodul
imped
cytokin
product
interact
bone
marrow
tumor
microenviron
pomalidomid
lenalidomid
interfer
cell
cycl
apoptosi
pomalidomid
time
potent
thalidomid
time
potent
lenalidomid
neutropenia
anemia
thrombocytopenia
fatigu
common
side
effectscompl
pomalidomid
venou
thromboembol
also
seen
patient
treat
imiddexamethason
pulmonari
toxic
uncommon
increasingli
report
clinic
complic
imid
agent
particularli
thalidomid
lenalidomid
pomalidomideinduc
pulmonari
toxic
thu
far
extrem
rare
literatur
case
report
far
mechan
pulmonari
toxic
clearli
understood
usual
time
interv
initi
treatment
onset
symptom
day
toxic
pomalidomid
may
delay
common
present
symptom
imid
pulmonari
toxic
dyspnea
cough
fever
hypoxia
simul
pneumonia
ground
glass
opac
common
radiolog
find
report
bal
result
variabl
span
lymphocytosi
elev
ratio
lymphocyt
deplet
revers
ratio
without
eosinophilia
diagnosi
often
confus
infecti
etiolog
major
patient
receiv
empir
antibiot
without
appar
benefit
tempor
relationship
initi
drug
symptom
onset
often
diagnost
clue
pomalidomideinduc
pulmonari
toxic
frequent
diagnosi
exclus
patient
improv
discontinu
drug
methylprednisolon
day
treatment
choic
symptom
sever
resolv
discontinu
drug
